This clinical trial is focused on studying the long-term safety and tolerability of a medication called soticlestat for individuals with Dravet Syndrome and Lennox-Gastaut Syndrome. These are both rare forms of epilepsy that begin in childhood and are characterized by frequent seizures. The medication, known by its code name TAK-935, is being tested as an additional treatment to standard care, which may include anti-seizure medications, vagus nerve stimulation, or specific diets like the ketogenic or modified Atkins diet.
The purpose of the study is to assess how well patients tolerate soticlestat over a long period. Participants in the study will take the medication in tablet form by mouth. The study will last up to 52 weeks, during which time participants will be monitored for any side effects and changes in their health. The study will also look at changes in seizure frequency and other health indicators, such as growth and development in children.
This trial is an extension of previous studies, meaning it includes participants who have already been involved in earlier research phases. The study aims to provide more information on the long-term use of soticlestat, helping to determine its safety and effectiveness as a treatment option for those living with Dravet Syndrome and Lennox-Gastaut Syndrome.



Belgium
France
Germany
Greece
Hungary
Italy
Latvia
Poland
Spain
The Netherlands